We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Actelion (ALIOF) Uptravi Approved for PAH in Switzerland
Read MoreHide Full Article
Actelion Ltd. announced that Swissmedic, the Agency for Therapeutic Products in Switzerland, has approved Uptravi for treatment of patients with pulmonary arterial hypertension (PAH).
Uptravi is indicated for the treatment of PAH in patients with advanced functional limitation (NYHA-functional class III/IV) to delay disease progression.
We note that in Dec 2015, Uptravi was approved in the U.S., for the treatment of PAH (WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.
We remind investors that in 2008, Actelion had inked an exclusive worldwide alliance with Nippon Shinyaku for Uptravi for the treatment of patients with PAH. As per the terms of the agreement, Actelion has rights to globally develop and commercialize the product outside Japan, while both companies will co-develop and co-commercialize the product in Japan. Nippon Shinyaku is eligible to receive milestones based on development and sales. In addition, Nippon Shinyaku will receive royalties on product sales.
The PAH market is already crowded with drugs like Adcirca, Revatio, Tyvaso and Veletri among others.
Meanwhile, several other companies are also looking to bring their own PAH treatments to market. Arena Pharmaceuticals, Inc. is currently evaluating its PAH candidate, ralinepag, in a phase II study. Results from the study are expected in mid 2017. Ralinepag enjoys Orphan Drug status in the U.S.
Actelion currently sports a Zacks Rank #1 (Strong Buy). A couple of other equally ranked stocks in the health care sector are Anika Therapeutics Inc. (ANIK - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Actelion (ALIOF) Uptravi Approved for PAH in Switzerland
Actelion Ltd. announced that Swissmedic, the Agency for Therapeutic Products in Switzerland, has approved Uptravi for treatment of patients with pulmonary arterial hypertension (PAH).
Uptravi is indicated for the treatment of PAH in patients with advanced functional limitation (NYHA-functional class III/IV) to delay disease progression.
We note that in Dec 2015, Uptravi was approved in the U.S., for the treatment of PAH (WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.
ACTELION LTD Price
ACTELION LTD Price | ACTELION LTD Quote
We remind investors that in 2008, Actelion had inked an exclusive worldwide alliance with Nippon Shinyaku for Uptravi for the treatment of patients with PAH. As per the terms of the agreement, Actelion has rights to globally develop and commercialize the product outside Japan, while both companies will co-develop and co-commercialize the product in Japan. Nippon Shinyaku is eligible to receive milestones based on development and sales. In addition, Nippon Shinyaku will receive royalties on product sales.
The PAH market is already crowded with drugs like Adcirca, Revatio, Tyvaso and Veletri among others.
Meanwhile, several other companies are also looking to bring their own PAH treatments to market. Arena Pharmaceuticals, Inc. is currently evaluating its PAH candidate, ralinepag, in a phase II study. Results from the study are expected in mid 2017. Ralinepag enjoys Orphan Drug status in the U.S.
Actelion currently sports a Zacks Rank #1 (Strong Buy). A couple of other equally ranked stocks in the health care sector are Anika Therapeutics Inc. (ANIK - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>